We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Individuals aren’t the only ones making New Year’s Resolutions. Three biotech companies want to start out the new year with a new start—as publicly traded companies.
With the end of the 2017 first quarter on the near horizon, speculation is increasing on merger-and-acquisition activity in biopharma. StreetInsider listed eight biopharma companies it thinks are likely targets. Let’s take a look.
Biotech stocks have taken a beating in 2016 and even the “Trump Bump” for pharma stocks was short-lived. But, a new year brings new hope for investors. A Motley Fool analyst thinks he has three stocks that could “shine” next year.